TFX Earnings Date: Nov 5, 2026 (Estimated) — Teleflex Incorporated
NYSE · Healthcare · Medical Instruments & Supplies
Updated
When is TFX's next earnings date?
Teleflex Incorporated (TFX) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $1.90 on revenue of $565.5M.
How did TFX do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Teleflex Incorporated posted EPS of $1.76 versus the $1.28 estimate, a beat of 38.6%. Revenue was $570.3M against a $559.6M estimate. The stock's 1-day post-earnings move was +1.5%.
How much does TFX stock move after earnings?
TFX beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 9.6% (up or down) in the day after earnings.
About Teleflex Incorporated
Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within critical care and surgical environments worldwide. Its comprehensive product portfolio includes: Vascular Access Solutions: Featuring the "Arrow" brand, these include catheters, advanced catheter navigation and tip positioning systems, and intraosseous access systems. They are essential for administering intravenous therapies, monitoring blood pressure, and drawing blood samples, all achievable through a single access point. Interventional Cardiology & Radiology Products: This segment covers various coronary catheters, therapies for structural heart conditions, and devices for peripheral intervention and cardiac assist. Key users include interventional cardiologists, radiologists, and vascular surgeons. Specific offerings comprise Arrow, Guideline, and Trapliner catheters, the Manta Vascular Closure Device, and Arrow Oncontrol systems. Anesthesia and Surgical Products: The company provides anesthesia and pain management products, serving hospitals, emergency medical services, and military health organizations. Its surgical division offers metal and polymer ligation clips, fascial closure systems for laparoscopic procedures, percutaneous surgical systems, and a range of other surgical instruments. Interventional Urology & General Urology: Teleflex's interventional urology offerings prominently feature the UroLift System, an innovative treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Additionally, it supplies general urology products like catheters, urine collection devices, catheterization accessories, and tools for operative endourology, alongside providing bladder management services. Respiratory Care Products: This category includes oxygen and aerosol therapy devices, spirometry equipment, and ventilation management systems, applicable across diverse healthcare settings. Teleflex serves a broad customer base, encompassing hospitals, healthcare providers, medical device manufacturers, and the home care market. Established in 1943, the company maintains its headquarters in Wayne, Pennsylvania.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | 1.28 | 1.76 | +38.58% | $570.3M | ✅ Beat | +1.55% | -0.34% | +2.58% |
| 2026-05-07 | Q1 2026 | 1.22 | 1.39 | +13.93% | $548.3M | ✅ Beat | +6.86% | +5.52% | +5.64% |
| 2026-02-26 | Q4 2025 | 3.74 | 1.93 | -48.40% | $569.0M | ❌ Miss | +6.38% | +6.52% | -0.96% |
| 2025-11-06 | Q3 2025 | 3.38 | 3.67 | +8.58% | $913.0M | ✅ Beat | -13.02% | -10.63% | -3.10% |
| 2025-07-31 | Q2 2025 | 3.36 | 3.73 | +11.01% | $780.9M | ✅ Beat | +4.90% | -1.61% | +11.12% |
| 2025-05-01 | Q1 2025 | 2.88 | 2.91 | +1.04% | $700.7M | ✅ Beat | -8.15% | -10.92% | -10.54% |
| 2025-02-27 | Q4 2024 | 3.88 | 3.89 | +0.26% | $795.4M | ✅ Beat | -21.68% | -24.47% | -21.34% |
| 2024-10-31 | Q3 2024 | 3.39 | 3.49 | +2.95% | $764.4M | ✅ Beat | -14.52% | -14.16% | -17.87% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $570.3M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Vascular Access | 43.2% | $246.3M | +32.8% | $189.3M | $182.4M | $185.5M | $191.0M |
| Interventional | 37.1% | $211.9M | +24.6% | $160.4M | $137.6M | $170.0M | $266.4M |
| Surgical | 19.7% | $112.1M | -1.7% | $121.9M | $105.8M | $114.0M | $122.9M |
By region
Q2 FY26 · $570.3M total
| Segment | Share | Revenue | YoY | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 |
|---|---|---|---|---|---|---|---|
| Americas | 61.2% | $348.8M | -33.6% | $433.3M | $622.9M | $475.7M | $525.6M |
| EMEA | 25.5% | $145.5M | -12.5% | $150.2M | $248.2M | $151.2M | $166.2M |
| Asia | 13.3% | $76.0M | -14.7% | $98.3M | $56.9M | $73.8M | $89.0M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.